10x Genomics Inc (NASDAQ:TXG) has a beta value of 1.85 and has seen 0.37 million shares traded in the recent trading session. The company, currently valued at $1.71B, closed the recent trade at $14.12 per share which meant it lost -$0.73 on the day or -4.92% during that session. The TXG stock price is -262.75% off its 52-week high price of $51.22 and 8.29% above the 52-week low of $12.95. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.16 million shares traded. The 3-month trading volume is 1.95 million shares.
The consensus among analysts is that 10x Genomics Inc (TXG) is Hold stock at the moment, with a recommendation rating of 2.30. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 5 out of 8 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.11.
10x Genomics Inc (NASDAQ:TXG) trade information
Sporting -4.92% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the TXG stock price touched $14.12 or saw a rise of 15.7%. Year-to-date, 10x Genomics Inc shares have moved -1.67%, while the 5-day performance has seen it change -12.62%. Over the past 30 days, the shares of 10x Genomics Inc (NASDAQ:TXG) have changed -3.75%. Short interest in the company has seen 6.6 million shares shorted with days to cover at 4.05.
Wall Street analysts have a consensus price target for the stock at $46, which means that the shares’ value could jump 69.3% from the levels at last check today. The projected low price target is $46.0 while the price target rests at a high of $46.0. In that case, then, we find that the latest price level in today’s session is -225.78% off the targeted high while a plunge would see the stock gain -225.78% from the levels at last check today.
10x Genomics Inc (TXG) estimates and forecasts
Figures show that 10x Genomics Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -30.17% over the past 6 months, with this year growth rate of 13.86%, compared to 24.70% for the industry. Revenue growth from the last financial year stood is estimated to be -1.29%.
6 analysts offering their estimates for the company have set an average revenue estimate of 164.98M for the current quarter. 12 have an estimated revenue figure of 140.83M for the next ending quarter. Year-ago sales stood 183.98M and 141.01M respectively for this quarter and the next, and analysts expect sales will shrink by -10.33% for the current quarter and -1.29% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -13.04% over the past 5 years. Earnings growth for 2025 is a modest 35.06% while over the next 5 years, the company’s earnings are expected to increase by 25.30%.
TXG Dividends
10x Genomics Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
10x Genomics Inc (NASDAQ:TXG)’s Major holders
Insiders own 2.16% of the company shares, while shares held by institutions stand at 97.93% with a share float percentage of 100.09%. Investors are also buoyed by the number of investors in a company, with 10x Genomics Inc having a total of 379.0 institutions that hold shares in the company. The top two institutional holders are FMR LLC with over 13.01 million shares worth more than $253.05 million. As of 2024-06-30, FMR LLC held 10.8971% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 10.19 million shares as of 2024-06-30. The firm’s total holdings are worth over $198.18 million and represent 8.5341% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Innovation ETF and Vanguard Total Stock Market Index Fund. As of Nov 30, 2024, the former fund manager holds about 7.76% shares in the company for having 8.3 shares of worth $118.5 million while later fund manager owns 3.25 shares of worth $46.34 million as of Sep 30, 2024, which makes it owner of about 3.04% of company’s outstanding stock.
